Pro-His-Ala-Gln-Leu-Leu-Arg-Val-Gly-Cys-Val-Leu-Gly-Thr-Cys-Gln-Val-Gln-Asn-Leu-Ser-His-Arg-Leu-Trp-Gln-Leu-Val-Arg-Pro-Ser-Gly-Arg-Arg-Asp-Ser-Ala-Pro-Val-Asp-Pro-Ser-Ser-Pro-His-Ser-Tyr-NH2
(Disulfide bond Cys10-Cys15)
Trifluoroacetate salt
Size : 0.5
P1(RMB) : 1032
MW : 5216.95
One letter sequence : PHAQLLRVGCVLGTCQVQNLSHRLWQLVRPSGRRDSAPVDPSSPHSY-NH2
Molecular Formula : C226H361N75O64S2
Description : Intermedins are members of the calcitonin/CGRP family. In vitro studies have shown that the synthetic 47 amino acid intermedin peptides act through the calcitonin receptor-like receptor/receptor activity-modifying protein (CRLR/RAMP) complexes by increasing intracellular cAMP levels. Unlike calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM) intermedin exhibited no preference for one of the three RAMPs when co-expressed with CRLR.
In normal and spontaneously hypertensive rats it has been demonstrated that intermedin treatment results in blood pressure reduction which can be blocked by the CGRP receptor antagonist CGRP (8-37). Apart from the hypotensive action, synthetic intermedin has also been shown to inhibit gastric emptying and food intake in mice.
Therefore, intermedin represents an additional regulator of gastrointestinal and cardiovascular functions and might be involved in other bioactivities mediated by the CRLR/RAMP receptor complexes.
Literature Reference : Y.Fujisawa et al., Am. J. Physiol. Heart Circ. Physiol., 290, H1120 (2006)
M.Chauhan et al., Endocrinology, 148, 1727 (2007)
M. Ogoshi et al.,Biochem. Biophys. Res. Commun., 311, 1072 (2003).
Y. Takei et al.,FEBS Lett., 556, 53 (2004).
J. Roh et al., J. Biol. Chem., 279, 7264 (2004)
Y. Fujisawa et al., Eur. J. Pharmacol., 497, 75 (2004).
M.M. Taylor et al.,Integr. Comp. Physiol., 288, R919 (2005).
K. Takahashi et al.,Peptides, 27, 1 383 (2006)
D. Bell et al., J. Pharmacol., 153, S247 (2008)
Cas :
